Health Care · Pharmaceutical Preparations

JNJ Johnson & Johnson SEC Filings & Insider Trading Activity 2026

company
CIK 200406131 filings
S&P 500

JNJ at a glance

Johnson & Johnson (JNJ, SEC CIK 200406) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on October 21, 2026, an 8-K current report on October 13, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 28, 2025 (FY2025), Johnson & Johnson (JNJ) reported revenue of $94.2 billion (up 6.0% from FY2024) and net income of $26.8 billion. Diluted EPS was $11.03.
  • As of September 30, 2026, 73 institutional investment managers tracked by SignalX reported holding Johnson & Johnson (JNJ) shares worth $238.7 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Forminard Elizabeth on November 12, 2026 of 13,072 shares at $284.39 per share.
  • In the last 90 days, JNJ insiders reported 0 open-market purchases ($0) and 3 open-market sales ($12.9M) on Form 4, a net sale of $12.9M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$94.2B
+6.0% vs prior year
Insiders · 90 days
0 buys · 3 sells
Net −$12.9M
13F holders
73 funds
$238.7B · −3 vs prior quarter
Latest 8-K
Oct 13, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 28, 2025

Full analysis →

Business Overview

  • New emphasis on transparency with online posting of Code of Business Conduct amendments and waivers within five business days
  • Strengthened insider trading policy for directors, officers, and certain insiders to ensure compliance with laws and listing standards
  • Unusual focus on detailed disclosure of corporate governance codes and ethical standards rather than product or market information

Management Discussion & Analysis

  • Revenue $94.2B in 2025, up 6.0% YoY from $88.8B in 2024; U.S. sales $53.8B (+6.9%), international $40.4B (+5.0%)
  • Operating margin 34.6% in 2025 vs 18.8% in 2024; Innovative Medicine margin 36.9% vs 33.2%; MedTech margin 12.2% vs 11.7%
  • Best segment: Innovative Medicine sales $60.4B (+6.0%), worst: Infectious Diseases sales $3.2B (-4.6%)
  • Cash/cash equivalents $20.1B end 2025; total debt $47.9B; acquisitions funded with senior notes; restructuring costs $205M (Surgery), $307M (Orthopaedics)
  • Risks: biosimilar competition impacting STELARA; expected generic competition for OPSUMIT in 2026; planned Orthopaedics separation in 18-24 months

Risk Factors

  • Board Regulatory Compliance & Sustainability Committee oversees cybersecurity risk and compliance with privacy laws
  • CISO provides quarterly updates on evolving cybersecurity threats and incidents impacting the company and industry
  • CIO and CISO responsible for cybersecurity incident detection, response, and recovery with 25+ years CISO experience
  • Cybersecurity risk management integrated into overall risk framework, with emphasis on threats relevant to 2026 landscape

AI summary of the JNJ 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 27, 2026

Management Discussion & Analysis

  • Emerging risks: pricing pressure, patent expirations, litigation, tariffs, supply-chain disruptions
  • Planned Orthopaedics separation: timing, execution, and anticipated benefits remain uncertain

AI summary of the JNJ 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 13, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 fiscal 2026 sales and earnings announcement for quarter ended September 27, 2026
  • Investor-relevant financial details contained in attached Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q3 sales $25.4B, up 5.9%, with operational growth 6.0%, led by Innovative Medicine growth of 7.9%
  • GAAP EPS $0.09 versus $2.12, reflecting special charges tied to talc litigation, Firefly Bio, and Sail Biomedicines

Item EX-99.2: Item EX-99.2

  • Q3 worldwide sales $25,399M, up 5.9%, with operational growth 6.0% and U.S. growth 9.1%
  • Innovative Medicine sales $16,757M, up 7.7%, led by Oncology growth 16.4% and Tremfya growth 68.3%
Filed Aug 4, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Jennifer Taubert retiring September 1, 2026 as Executive Vice President and Worldwide Chairman, Innovative Medicine
  • Departure also removes Taubert from Johnson & Johnson’s Executive Committee
Filed Jul 29, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Completed Firefly Bio acquisition for $1 billion cash, expanding J&J’s oncology platform into pan-KRAS and other difficult-to-treat cancers
  • Firelink™ degrader antibody conjugate platform enables targeted protein degradation, supporting next-generation solid-tumor therapies

Item 7.01: Regulation FD Disclosure

  • Firefly acquisition completed and Sail strategic collaboration signed, marking expanded investment in biotech pipeline
  • 2026 adjusted EPS guidance reduced $0.64 to $10.96–$11.11, with transactions cutting adjusted operational EPS by $0.64

Item EX-99.2: Item EX-99.2

  • Strategic collaboration with Sail to advance in vivo CAR-T programs targeting immune-mediated diseases and immune-system reset
  • Initial payments $785 million, including $465 million equity investment, plus $140 million contingent development milestones

AI summaries of JNJ 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for JNJ

Don't miss the next JNJ filing

  • Alerts as it files. A push when JNJ files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut JNJ, by share count.
  • Ask anything. An AI agent that reads every JNJ filing and answers with sources.

JNJ alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Forminard ElizabethMNov 12, 2026$151.41
Forminard ElizabethSellNov 12, 2026$284.39
Forminard ElizabethMNov 12, 2026-
Pinto Daniel EASep 8, 2026$276.31
Woods Eugene A.ASep 8, 2026$276.31
HEWSON MARILLYN AASep 8, 2026$276.31
Schmid TimothyMSep 2, 2026-
Schmid TimothyMSep 2, 2026$151.41

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$88.8B$94.2B
Gross Profit$58.6B$61.4B$63.9B
Net Income-$14.1B$26.8B
Gross Margin-69.1%67.9%
Net Margin-15.8%28.5%
Balance Sheet
Total Assets$167.6B$180.1B$199.2B
Equity-$71.5B$81.5B
ROE-19.7%32.9%
Per Share
EPS$13.72$5.79$11.03
Cash Flow
Operating CF$22.8B$24.3B$24.5B
CapEx-$4.4B$4.8B

Source: XBRL data in Johnson & Johnson (JNJ)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate JNJ share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
JNJ shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202673$238.72B
Q2 202676$235.43B
Q1 202675$226.68B
Q4 202571$193.32B
Q3 202576$185.06B
Q2 202575$142.41B
Q1 202572$118.25B
Q4 202470$81.78B
Position changes: Q2 2026 → Q3 2026
Top Sellers
New Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 588 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

JNJ filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 13, 2026--
13F-HROct 26, 2026--
10-QOct 21, 2026Analysis
8-KOct 13, 2026Analysis-
4Sep 10, 2026--
4Sep 10, 2026--
4Sep 10, 2026--
4Sep 4, 2026--
4Aug 18, 2026--
4Aug 14, 2026--
4Aug 7, 2026--
4Aug 7, 2026--
13F-HRAug 6, 2026-
8-KAug 4, 2026Analysis-
8-KJul 29, 2026Analysis-
8-KJul 28, 2026Analysis-
10-QJul 23, 2026Analysis
4Jul 21, 2026--
8-KJul 15, 2026Analysis-
4Jun 12, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
13F-HRMay 13, 2026-
4May 4, 2026--

Related Health Care companies

All Health Care →

JNJ SEC filings: frequently asked questions

Are JNJ insiders buying or selling?

In the last 90 days, Johnson & Johnson (JNJ) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $12.9 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold JNJ stock?

As of September 30, 2026, the largest Johnson & Johnson (JNJ) holders among the 13F filers tracked by SignalX were BlackRock ($55.5 billion), Vanguard Capital Management LLC ($41.8 billion), State Street Corp ($35.5 billion), Vanguard Portfolio Management LLC ($17.4 billion), JPMorgan Chase & Co ($16.5 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was JNJ's revenue in fiscal year 2025?

For the fiscal year ended December 28, 2025 (FY2025), Johnson & Johnson (JNJ) reported revenue of $94.2 billion (up 6.0% from FY2024) and net income of $26.8 billion. Diluted EPS was $11.03. The figures come from the XBRL data in the 10-K.

What are the main risks in JNJ's latest 10-K?

In the 10-K filed February 11, 2026, Johnson & Johnson (JNJ) flagged: Board Regulatory Compliance & Sustainability Committee oversees cybersecurity risk and compliance with privacy laws. CISO provides quarterly updates on evolving cybersecurity threats and incidents impacting the company and industry. (AI summary of the Risk Factors section.)

What did JNJ report in its latest 8-K?

Johnson & Johnson (JNJ) filed an 8-K on October 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 sales and earnings announcement for quarter ended September 27, 2026.

What are the latest JNJ SEC filings?

Johnson & Johnson (JNJ) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on October 21, 2026, an 8-K current report on October 13, 2026 and a Form 4 insider filing on November 13, 2026.

What is JNJ's SEC CIK number?

Johnson & Johnson (JNJ)'s SEC Central Index Key (CIK) is 200406. EDGAR lists every JNJ filing under that number.

Ask anything about JNJ

The research agent reads JNJ's filings, financials, insider trades and 13F holders, then answers with sources.